Clinical Trial

Phase 2 Study of WGI-0301 for Advanced HCC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the MTD of WGI-0301 in combination with Sorafenib for advanced Hepatocellular Carcinoma (HCC) and assess its safety and efficacy in adults with advanced unresectable HCC who have previously received PD-1 / PD-L1 immune checkpoint inhibitors.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-03-06; most recent amendment 2026-03-16.
Status change: Not Yet Recruiting → Recruiting 2026-03-16
Trial Details
NCT Number NCT06309485
Lead Sponsor Zhejiang Haichang Biotech Co., Ltd.
Conditions Advanced Hepatocellular Carcinoma (HCC)
Enrollment 60 participants
Start Date 2024-07-31
Primary Completion 2026-12 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-03-19